HEMEL HEMPSTEAD, England –– EUSA Pharma (EUSA), a world-class specialty pharmaceutical company...
EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors
read more
detail
Cota Announces $40 Million Series C Financing to Advance Classification System
NEW YORK, NY—Cota Inc., a healthcare real-world evidence and data analytics company bridging...
AxoGen, Inc. Announces Proposed Public Offering of Common Stock
ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and...
EUSA Pharma and AVEO Oncology Announce First Commercial Launch of FOTIVDA (tivozanib)
HEMEL HEMPSTEAD, England & CAMBRIDGE, Massachusetts. – – EUSA Pharma and AVEO Oncology...
AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida
ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and...
EW Healthcare Partners Announces the Appointment of Three Senior Executives
NEW YORK, New York—EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a...
Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities
TORONTO, Canada—Venus Concept Ltd., a privately-held and innovative global aesthetic technology...
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment
HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus...
European Commission Approves the Only Immunotherapy for High-Risk Neuroblastoma
HEMEL HEMPSTEAD, England – EUSA Pharma today announced that the European Commission (EC) has...
EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for Dinutuximab Beta
HEMEL HEMPSTEAD, England and VIENNA, Austria – – EUSA Pharma (EUSA), a specialty pharmaceutical...